Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Daniel V. Catenacci, MD, of the University of Chicago Medical Center, Chicago, IL, discusses an abstract presented at the European Society for Medical Oncology Congress (ESMO) 2021 Meeting investigating the incidence of gastroesophageal carcinoma with HER2 gene amplification. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Catenacci reports disclosures with Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Novartis, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus BiosciencesTempus, Guardant Health, Archer & Natera.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.